Synapse - Robert Motzer

Results (1247)

Hypoxia-inducible factor-2 alpha (HIF-2α) target activation and clinical outcomes in 942 patients with clear cell renal cell carcinoma

Meeting Abstract

Doshi, S. D.; Kuo, F.; Knezevic, A.; Kotecha, R. R.; Motzer, R. J.; Hakimi, A. A.; Voss, M. H.
Journal of Clinical Oncology (2024)

Fulltext@MSK | Save

Subgroup analyses of efficacy outcomes by baseline tumor size in the phase 3, open-label CLEAR trial

Meeting Abstract

Grünwald, V.; Motzer, R. J.; Haanen, Jbag; Schmidinger, M.; Staehler, M. D.; Goh, J. C.; Voog, E.; Climent, M. A.; George, S.; Burgents, J. E.; more...
Journal of Clinical Oncology (2024)

Fulltext@MSK | Save

Evolving metastatic renal cell carcinoma (mRCC) treatment landscape in the post vascular endothelial growth factor (VEGF) and immune checkpoint inhibitor (IO) setting

Meeting Abstract

Shah, N. J.; Bhattacharya, R.; Ning, N.; Shinde, R.; Schmier, J.; Tan, M. L. D.; Lemasters, T.; Sundaram, M.; Perini, R. F.; Motzer, R. J.
Journal of Clinical Oncology (2024)

Fulltext@MSK | Save

Nivolumab plus cabozantinib (N plus C) vs sunitinib (S) for previously untreated advanced renal cell carcinoma (aRCC): Results from 55-month follow-up of the CheckMate 9ER trial

Meeting Abstract

Bourlon, M. T.; Escudier, B.; Burotto, M.; Powles, T.; Apolo, A. B.; Shah, A. Y.; Porta, C.; Suárez, C.; Barrios, C. H.; Richardet, M.; more...
Journal of Clinical Oncology (2024)

Fulltext@MSK | Save

Nivolumab plus ipilimumab (NIVO + IPI) vs sunitinib (SUN) for first-line treatment of advanced renal cell carcinoma (aRCC): Long-term follow-up data from the phase 3 CheckMate 214 trial

Meeting Abstract

Escudier, B.; McDermott, D. F.; Burotto, M.; Choueiri, T. K.; Hammers, H. J.; Plimack, E. R.; Porta, C.; George, S.; Powles, T.; Donskov, F.; more...
Journal of Clinical Oncology (2024)

Fulltext@MSK | Save

Paclitaxel, ifosfamide, and cisplatin as initial salvage chemotherapy for germ cell tumors: Long-term follow-up and outcomes for favorable- and unfavorable-risk disease

Journal Article

Gleeson, J. P.; Knezevic, A.; Bromberg, M.; Patil, S.; Sheinfeld, J.; Carver, B. S.; Bains, M.; Jones, D. R.; Bajorin, D. F.; Bosl, G. J.; more...
Journal of Clinical Oncology (2024)

Fulltext@MSK | Save

Real-world treatment patterns and clinical outcomes of metastatic renal cell carcinoma patients post immune-oncology (IO) and vascular endothelial growth factor (VEGF) receptor targeted therapies

Meeting Abstract

Shah, N.; Sura, S.; Shinde, R.; Wentworth, C.; Conkling, P.; Bupathi, M.; Perini, R.; Vickery, D.; Motzer, R.
The Oncologist (2024)

Fulltext@MSK | Save

A phase 1b, open-label, safety, tolerability, and efficacy study of HC-7366 in combination with belzutifan (WELIREG(TM)) in patients with advanced or metastatic renal cell carcinoma, NCT06234605

Meeting Abstract

McKay, R. R.; Garmezy, B.; Barata, P.; Ornstein, M.; Shah, N. J.; Hammers, H.; Hutson, T. E.; Chisamore, M.; Karim, D.; Mattson, P.; more...
The Oncologist (2024)

Fulltext@MSK | Save

Nivolumab plus ipilimumab vs sunitinib for first-line treatment of advanced renal cell carcinoma: 8-year follow-up with analyses in favorable risk patients from the phase 3 CheckMate 214 trial

Meeting Abstract

Atkins, M. B.; Escudier, B.; McDermott, D. F.; Burotto, M.; Choueiri, T. K.; Hammers, H. J.; Plimack, E. R.; Porta, C.; George, S.; Powles, T.; more...
The Oncologist (2024)

Fulltext@MSK | Save

Lenvatinib plus pembrolizumab (L plus P) vs sunitinib (S) in advanced renal cell carcinoma (aRCC): Patterns of progression and subsequent therapy in the CLEAR trial

Meeting Abstract

Grünwald, V.; Motzer, R. J.; Keizman, D.; Bedke, J.; Schmidinger, M.; Staehler, M. D.; Matveev, V. B.; George, S.; Hutson, T. E.; Vaishampayan, U. N.; more...
Journal of Clinical Oncology (2024)

Fulltext@MSK | Save